Duke Energy (NYSE: DUK ) is anything but a clean energy company. It owns 19 coal-fired power plants, 22 oil- or gas-fired plants, and seven nuclear�plants (the cleanest of the bunch), and is building more coal and gas�capacity right now. So, how did this company become a player in renewable energy almost overnight?
The utility and power plant owner followed Edison International (NYSE: EIX ) in making an equity investment in Clean Power Finance, a residential solar finance and service company. Clean Power Finance claims to generate the financing for 40% of the residential leases in the U.S. market ���s a major player in this emerging market Duke is getting exposure to solar it sorely needs.
Earlier this week, President Obama outlined his plans to fight climate change; a big part of that plan is to reduce emissions of carbon dioxide, particularly from coal plants. That hits Duke Energy where its profit center is, as is evident by the company retiring the W.S. Lee plant, one of well over 100 coal plants to be shut down in recent years.
Best Safest Stocks To Watch Right Now: Immunomedics Inc.(IMMU)
Immunomedics, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and marketing of monoclonal, antibody-based products for the treatment of cancer, autoimmune, and other serious diseases in the United States and Europe. The company?s products include epratuzumab, a Phase III clinical trail product for the treatment of systemic lupus erythematosus and non-Hodgkin?s lymphoma; Veltuzumab, a Phase I/II clinical study completed product for the treatment of patients with non-Hodgkin?s lymphoma, immune thrombocytopenic purpura, and chronic lymphocytic leukemia; Yttrium Y 90 Clivatuzumab tetraxetan, a humanized monoclonal antibody for pancreatic cancer that is in Phase Ib/II clinical trail; and Yttrium Y 90 epratuzumab tetraxetan, a Phase I/II clinical study product for patients with non-Hodgkin?s lymphoma. Its early phase clinical trial products comprise Milatuzumab, a transmembrane protein product for antibody-drug conjugate therapy. The com pany also develops Dock-and-Lock methodology for making fusion proteins and multifunctional antibodies, as well as a new method of delivering imaging and therapeutic agents selectively to disease, primarily different solid cancers. In addition, it markets and sells a diagnostic product, LeukoScan, which is used to treat infection and inflammation in bones for patients with suspected osteomyelitis, including patients with diabetic foot ulcers. Immunomedics, Inc. has a license and collaboration agreement with Nycomed GmbH to develop, manufacture, and commercialize veltuzumab in the subcutaneous formulation for the treatment of various non-cancer indications; and a partnership and cross-licensing agreement with Alexis Biotech Ltd., to develop vaccines against cancers that include melanoma and chronic lymphocytic leukemia, and infectious diseases, such as AIDS. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey.
Advisors' Opinion:- [By Roberto Pedone]
Another under-$10 stock that's starting to move within range of triggering a big breakout trade is Immunomedics (IMMU), which is focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. This stock is off to a very bullish start in 2013, with shares up sharply by 110%.
If you take a look at the chart for Immunomedics, you'll notice that this stock has been uptrending decent for the last month, with shares moving higher from its low of $4.85 to its recent high of $6.54 a share. During that uptrend, shares of IMMU have been consistently making higher lows and higher highs, which is bullish technical price action. This uptrend is coming after shares of IMMU downtrended during July from $6.91 to that $4.65 a share low. Shares of IMMU are now starting to push within range of triggering a big breakout trade.
Market players should now look for long-biased trades in IMMU if it manages to break out above some near-term overhead resistance at $6.54 a share and then once it clears its 52-week high at $6.91 a share with high volume. Look for a sustained move or close above those levels with volume that registers near or above its three-month average volume of 1.15 million shares. If that breakout triggers soon, then IMMU will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that breakout are $8 to $10 a share, or possibly even north of $10 a share.
Traders can look to buy IMMU off any weakness to anticipate that breakout and simply use a stop that sits right below its 50-day at $5.52 a share or below more support at $5 a share. One can also buy IMMU off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
5 Best Diversified Bank Stocks To Buy For 2014: Eaton Vance Tax-Advantaged Global Dividend Opportunities Fund (ETO)
Eaton Vance Tax-Advantaged Global Dividend Opportunities Fund (the Fund) is a closed-end management investment company. The Fund's investment objective is to provide a high level of after-tax total return. The Fund pursues its objective by investing primarily in dividend-paying common and preferred stocks.
The Fund�� top 10 equity holdings include Freeport-McMoran Copper, Veolia Environment, Southern Copper Corp., Societe Generale, Chevron Corp., Occidental Petroleum Corp., Exelon Corp., Total SA Spon ADR, Entergy Corp. and Suncor Energy Inc. Top 10 equity holdings represented 25.3% of total investments as of April 30, 2007.
Advisors' Opinion:- [By GURUFOCUS]
Special Purpose Funds- Eaton Vance Tax-Adv. Global Dividend Oppor. Fund (ETO) | Yield: 7.3%
- The Gabelli Global Utility & Income Trust (GLU) | Yield: 6.2%
- Pimco Global Stocksplus Income Fund (PGP) | Yield: 9.5%
- LMP Real Estate Income Fund Inc. (RIT) | Yield: 7.0%
5 Best Diversified Bank Stocks To Buy For 2014: Marketo Inc (MKTO)
Marketo, Inc. (Marketo), incorporated on December 17, 2009, provides cloud-based marketing software platform that enables organizations to engage in modern relationship marketing. The Company�� software platform is designed to enable the execution, management and analytical measurement of marketing activities, helping organizations to acquire new customers. The Company�� platform includes marketing automation, social marketing, sales insight and revenue analytics. Its customer base includes 2,000 customers across a range of industries, including business services, consumer, financial services, healthcare, manufacturing, media, technology and telecommunications. The Company provides its solutions on a subscription basis. Effective December 19, 2013, Marketo Inc acquired Insightera Ltd.
The Company designs, builds and markets a suite of integrated applications to address the needs of modern marketing professionals. The Company�� customers use these applications individually and in combination to streamline and automate marketing processes; develop, retain and extend customer relationships, and measure the positive impact on revenue of marketing programs. Its platform and suite of applications is hosted and delivered over the Web using a cloud-based, or software as a service (SaaS) model, and is built using a multi-tenant architecture. The Company markets and sells its enterprise applications as: Marketo lead management, which includes the core Marketo platform, plus all of the marketing automation capabilities available on the platform; Marketo social marketing, which enables social media campaigns, such as referrals, sweepstakes, and other customer engagement campaigns, and also includes features to add social marketing extensions to traditional marketing campaigns; Marketo sales insight, which provides insights to salespeople about their customers and prospects, and Marketo revenue cycle analytics, which is a suite of analytic tools, analyzers, and ad hoc reporting capabilities taki! ng advantage of its time-series analytics engine.
The Company has built a suite of applications that run on its platform. The applications include marketing automation, social marketing, sales insight and revenue analytics. Marketing automation provides a set of capabilities for marketers to create, automate, and track personalized multi-channel marketing campaigns and relationship-marketing workflows. It includes functionality for marketers to finely segment their prospect and customer database based on collected demographic and behavioral data; generate custom Web pages without programming; send batch and individual personalized marketing messages over email, short message service (SMS) text, and other channels; streamline the entire process of running online (e.g., webinar) and offline (e.g., trade show) marketing events, and to execute multi-step lead nurturing and relationship-marketing campaigns that can run over days, weeks, or months.
Social marketing enables marketers to run social media marketing campaigns, as well as to an increase traditional marketing campaigns with a social marketing aspect in order to amplify marketing messages across social networks. Its solution lets marketers add intelligent social sharing buttons to existing Web content and videos; publish new Facebook pages with the touch of a button; build social engagement applications, such as polls, sweepstakes, and referral offers to engage their audience and promote social cross-posting, and increase existing customer and prospect information with social profiles and sharing behavior.
Sold on a per-seat basis, the Company offers sales insight application to customers utilizing Microsoft dynamics customer relationship management (CRM) or salesforce.com as their CRM system. Revenue Analytics provides a range of ways to help companies understand the correlation between marketing programs and revenue outcomes, and includes: a library of operational reports detailing e-mail and landing page per! formance,! Web activity, and lead performance; intuitive analyzers that show the influence of marketing on individual customer outcomes; analytics that compute and illustrate the impact, effectiveness and return on investment of marketing programs individually and in aggregate, and an ad-hoc report builder for completely customized reports and dashboards.
The Company competes with Act-On, Eloqua, Aprimo, HubSpot, SAS Institute, Unica, ExactTarget, Responsys, Silverpop, Oracle Corporation and SAP AG.
Advisors' Opinion:- [By Lee Jackson]
The Lazard trading desk said that active traders may want to look at software stocks that still had unusually high short interest. Those included Concur Technologies (NASDAQ: CNQR), Tangoe Inc. (NASDAQ: TNGO), Jive Software (NASDAQ: JIVE), Marketo Inc. (NASDAQ: MKTO), VeriSign Inc. (NASDAQ: VRSN) and VMware Inc. (NYSE: VMW). Stocks with high short interest can explode to the upside if the company gets back on track and short sellers are forced to cover.
- [By gurujx]
Marketo Inc (MKTO): SVP & CFO Frederick Ball Sold 50,000 Shares
SVP & CFO of Marketo Inc (MKTO) Frederick Ball sold 50,000 shares on 09/18/2013 at an average price of $33.99.
5 Best Diversified Bank Stocks To Buy For 2014: Bio-Matrix Scientific Group Inc (BMSN)
Bio-Matrix Scientific Group, Inc., incorporated on October 6, 1998, is a development stage company. The Company, through its wholly-owned subsidiary Regen BioPharma ,Inc., is engaged in the development of regenerative medical applications which it focuses to license from other entities up to the point of completion of Phase I and or Phase II clinical trials after which it would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials.
The Company has begun development of HemaXellerate, a cellular drug designed to heal damaged bone marrow. HemaXellerate I (TM) is a patient-specific composition of cells that have been demonstrated to repair damaged bone marrow and stimulate production of blood cells based on previous animal studies.
Advisors' Opinion:- [By Bryan Murphy]
If you're a small cap enthusiast looking for some budding ideas, you may not need to look any further than China GengSheng Minerals, Inc. (NYSEMKT:CHGS), Bio Matrix Scientific Group Inc. (OTCMKTS:BMSN), and MER Telemanagement Solutions Ltd. (NASDAQ:MTSL). All three have either pushed themselves to the brink of a breakout, if they haven't started one already. Here's a closer technical look at MTSL, BMSN, and CHGS, and what it's going to take to get them going if they're not going already.
No comments:
Post a Comment